{"id":11064,"date":"2025-10-02T14:50:09","date_gmt":"2025-10-02T14:50:09","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/?p=11064"},"modified":"2026-01-05T11:18:05","modified_gmt":"2026-01-05T11:18:05","slug":"hipertermie-oncologie-studii-faza-3","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/","title":{"rendered":"Integrarea Terapeutic\u0103 a Hipertermiei \u00een Oncologia Modern\u0103: O Analiz\u0103 Critic\u0103 a Studiilor de Faz\u0103 III \u0219i Meta-Analizelor (Endpoint-uri OS, DFS, CR)"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/\",\n      \"name\": \"Dovezi Nivel 1A: Sinteza Studiilor Clinice de Faz\u0103 III \u00een Hipertermia Oncologic\u0103\",\n      \"description\": \"Sintez\u0103 a dovezilor clinice de Nivel 1A \u0219i a studiilor randomizate de faz\u0103 III care confirm\u0103 eficacitatea hipertermiei \u00een oncologie pentru supravie\u021buire \u0219i control local.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"ro\",\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/#article\" }\n      ]\n    },\n    \/* DISPOZITIVUL - CONFIGURAT PENTRU VALIDARE *\/\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/HyDeep-600WM-Andromedic.jpg\",\n      \"description\": \"Dispozitiv profesional de hipertermie RF modulat\u0103 de 13.56 MHz. Proiectat pentru implementarea protocoalelor termice validate \u00een studiile clinice de faz\u0103 III.HyDeep 600 WM utilizeaz\u0103 frecven\u021ba standard de 13.56 MHz \u0219i protocoale de modula\u021bie avansat\u0103, fiind tehnic compatibil cu parametrii terapeutici utiliza\u021bi \u00een studiile clinice de referin\u021b\u0103 de Faz\u0103 III (EORTC, Dutch Deep HT Group etc.)\",\n      \"sku\": \"HYDEEP-600WM-L1A-RO\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/contact-andromedic-romania\/\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\",\n        \"itemCondition\": \"https:\/\/schema.org\/NewCondition\"\n      }\n    },\n    \/* ARTICOLUL \u0218TIIN\u021aIFIC CU STUDIILE CLINICE *\/\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/hipertermie-oncologie-studii-faza-3\/#article\",\n      \"headline\": \"Sinteza Dovezilor de Nivel 1A: Studii de Faz\u0103 III \u00een Hipertermia Oncologic\u0103\",\n      \"author\": [{ \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\" }],\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"mentions\": [\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-sts-eortc\",\n          \"name\": \"EORTC 62961 Faza III: Sarcom de \u021aesut Moale\",\n          \"outcome\": \"OS \u00eembun\u0103t\u0103\u021bit (HR 0.73, p=0.04). OS median triplat la 15.4 ani vs 6.2 ani.\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-lacc-meta\",\n          \"name\": \"Meta-Analiz\u0103 Cancer Cervical (LACC)\",\n          \"outcome\": \"Confirmat RR 0.56 pentru R\u0103spuns Complet (p < 0.001) \u0219i HR 0.67 pentru OS (p = 0.05).\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-hnc\",\n          \"name\": \"HNC Faza III (Kang\/Huilgol) - Cancer Cap \u0219i G\u00e2t\",\n          \"outcome\": \"DFS la 5 ani crescut de la 25.5% la 51.3% (p < 0.005). Rat\u0103 CR 81.6%.\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-rectal-ott\",\n          \"name\": \"Ott 2019 Faza III Cancer Rectal\",\n          \"outcome\": \"OS 95.8% vs 74.5% (p = 0.045) \u0219i LRFS 97.7% vs 78.7% (p = 0.006).\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-melanoma-overgaard\",\n          \"name\": \"Overgaard 1995 Faza III Melanom\",\n          \"outcome\": \"Control Local la 2 ani \u00eembun\u0103t\u0103\u021bit de la 28% la 46% (p = 0.008).\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-breast-datta\",\n          \"name\": \"Meta-Analiz\u0103 Cancer Mamar (Datta 2016)\",\n          \"outcome\": \"Rat\u0103 R\u0103spuns Complet (CR) 66.6% cu HT vs 38.1% doar cu RT.\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-glioblastoma-mht\",\n          \"name\": \"Analiz\u0103 Clinic\u0103 GBM (Glioblastom)\",\n          \"outcome\": \"Supravie\u021buire la 1 an 73% vs 37% (p=0.0021). OS median Astrocitom 91.6 luni.\"\n        },\n        {\n          \"@type\": \"MedicalStudy\",\n          \"@id\": \"https:\/\/andromedichyperthermia.com\/#trial-pancreatic-mht\",\n          \"name\": \"Studiu Comparativ Cancer Pancreatic\",\n          \"outcome\": \"OS median dublat de la 9 la 20 luni (p < 0.001). Rat\u0103 PR 45% vs 24%.\"\n        }\n      ]\n    },\n    \/* EXPERT MEDICAL CU ADRESA CLINCENI *\/\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"jobTitle\": \"Co-fondator SRHO, Expert Medical\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/medic-hipertermie-veronica-iatan\/\",\n      \"address\": {\n        \"@type\": \"PostalAddress\",\n        \"streetAddress\": \"Strada Stadionului nr. 25G\",\n        \"addressLocality\": \"Clinceni\",\n        \"addressRegion\": \"Ilfov\",\n        \"postalCode\": \"077060\",\n        \"addressCountry\": \"RO\"\n      }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"name\": \"Cristian Gologan\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/ro\/director-societate-romana-hipertermie\/\",\n      \"jobTitle\": \"CEO Premium Wellness Distrib SRL, CEO &#038; Co-fondator SRHO\"\n    }\n  ]\n}\n<\/script><\/p>\n<div class=\"author-info\"><strong>Autoritate \u0219i Expertiz\u0103 (E-E-A-T):<\/strong><br \/>\n<strong>De Dr. Veronica Iatan, MD, si Cristian Gologan M.S.c, Andromedichyperthermia<\/strong><\/div>\n<h1>Integrarea Terapeutic\u0103 a Hipertermiei \u00een Oncologia Modern\u0103: O Analiz\u0103 Critic\u0103 a Studiilor de Faz\u0103 III \u0219i Meta-Analizelor (Endpoint-uri OS, DFS, CR)<\/h1>\n<h2>1. Rezumat Executiv \u0219i Principii Fundamentale ale Hipertermiei (HT)<\/h2>\n<p><strong>Hipertermia (HT) oncologic\u0103<\/strong>, definit\u0103 ca aplicarea controlat\u0103 de c\u0103ldur\u0103 la temperaturi cuprinse \u00eentre <strong>39\u00b0C \u0219i 45\u00b0C<\/strong>, reprezint\u0103 o modalitate terapeutic\u0103 adjuvant\u0103 care <strong>a demonstrat un beneficiu clinic semnificativ, confirmat prin dovezi de Nivel 1A<\/strong> (<strong>studii randomizate de Faz\u0103 III \u0219i meta-analize<\/strong>), pentru o serie de tumori solide avansate \u0219i recurente.<\/p>\n<div class=\"key-points\">\n<h3>Puncte Cheie - Dovad\u0103 de Nivel 1A:<\/h3>\n<ul>\n<li><strong>Rol:<\/strong> HT nu distruge direct tumora, ci ac\u021bioneaz\u0103 ca un <strong>sensibilizator biologic<\/strong> puternic.<\/li>\n<li><strong>Beneficii Confirmate:<\/strong> Sinteza datelor de Nivel 1A eviden\u021biaz\u0103 o \u00eembun\u0103t\u0103\u021bire consistent\u0103 a <strong>Supravie\u021buirii Globale (OS)<\/strong> \u0219i a <strong>Ratei de R\u0103spuns Complet (CR)<\/strong>.<\/li>\n<li><strong>Indica\u021bii Majore:<\/strong> Sarcoame de \u021besuturi moi, cancer de col uterin , cancer san recidivat, melanom malign, cancer vezical, cancer rectal si tumori ORL.<\/li>\n<li><strong>Siguran\u021b\u0103:<\/strong> Beneficiul terapeutic este ob\u021binut <strong>f\u0103r\u0103 o cre\u0219tere semnificativ\u0103 a toxicit\u0103\u021bii sistemice sau a evenimentelor adverse severe<\/strong> (Grad 3 sau 4).<\/li>\n<li><strong>Concluzie:<\/strong> HT este un adjuvant indispensabil \u00een regimurile multimodale standard pentru tumorile selectate.<\/li>\n<\/ul>\n<\/div>\n<h3>1.1. Clasificarea \u0219i Modalit\u0103\u021bile de Hipertermie Oncologic\u0103<\/h3>\n<h4>1.1.1. Hipertermia Loco-regional\u0103 (L-R HT)<\/h4>\n<p>Aceasta este utilizat\u0103 pentru \u00eenc\u0103lzirea profund\u0103 a tumorilor pelvine, toracice \u0219i abdominale. Tehnicile comune includ sistemele capacitive de radiofrecven\u021b\u0103 (RF) \u0219i cele radiative cu re\u021bea de antene (antenna-array matching). Aceste metode sunt concepute pentru a livra energie termic\u0103 la ad\u00e2ncime, viz\u00e2nd temperaturi terapeutice \u00een volumul tumoral, men\u021bin\u00e2nd \u00een acela\u0219i timp \u021besuturile s\u0103n\u0103toase \u00een limite de toleran\u021b\u0103. Obiectivul este o \u00eenc\u0103lzire c\u00e2t mai omogen\u0103 (izoterm\u0103) a \u00eentregii mase tumorale.<\/p>\n<h4>1.1.2. Hipertermia RF-Modulat\u0103 (mHT)<\/h4>\n<p>Hipertermia RF modulata (mHT) reprezint\u0103 o abordare non-invaziv\u0103 distinct\u0103. Spre deosebire de \u00eenc\u0103lzirea izoterm\u0103 tradi\u021bional\u0103, mHT utilizeaz\u0103 o cuplare capacitiv\u0103 la o frecven\u021b\u0103 purt\u0103toare de 13.56 MHz, modulat\u0103 de fluctua\u021bii fractale \u00een timp. Principiul de func\u021bionare se bazeaz\u0103 pe transferul de energie focalizat la nivelul membranei celulare. Pierderea dielectric\u0103 ridicat\u0103 (high dielectric loss) se produce preferen\u021bial \u00een membranele celulelor canceroase (datorit\u0103 propriet\u0103\u021bilor lor electrice modificate), gener\u00e2nd un gradient de temperatur\u0103 specific, care excit\u0103 c\u0103ile apoptotice. Acest mecanism de \u00eenc\u0103lzire \"din interior spre exterior\" (heating \"inside out\") rezult\u0103 \u00een temperaturi intratumorale mai mari \u0219i leziuni reduse asupra \u021besutului normal, diferen\u021biind-o fundamental de metodele radiative sau capacitive standard.<\/p>\n<h4>1.1.3. Hipertermia Intersti\u021bial\u0103<\/h4>\n<p>Aceast\u0103 modalitate implic\u0103 livrarea invaziv\u0103 a c\u0103ldurii, adesea prin intermediul unor antene, tije sau semin\u021be inserate direct \u00een tumor\u0103. Este utilizat\u0103 predominant pentru tratamentul tumorilor cerebrale (glioame) sau pentru boala superficial\u0103 recurent\u0103.<\/p>\n<h3>1.2. De Ce Func\u021bioneaz\u0103 Fereastra Terapeutic\u0103 de 39-45\u00b0C? (Mecanismele Biologice)<\/h3>\n<p>Eficacitatea clinic\u0103 demonstrat\u0103 de HT la nivel de Faz\u0103 III este inseparabil\u0103 de \u00een\u021belegerea mecanismelor sale biologice complexe. Aceste mecanisme transcend simpla distrugere celular\u0103, pozi\u021bion\u00e2nd HT ca un <strong>sensitizer multifunc\u021bional<\/strong> al tratamentelor standard.<\/p>\n<p>Temperatura optim\u0103 de <strong>39-45\u00b0C<\/strong> este selectat\u0103 deoarece maximizeaz\u0103 dezechilibrele celulare specifice tumorii. Succesul global observat \u00een studiile randomizate se datoreaz\u0103 acestui rol de sensibilizare, care \u00eembun\u0103t\u0103\u021be\u0219te eficacitatea radioterapiei (RT) \u0219i chimioterapiei (CHT) prin interac\u021biunea cu microambientul tumoral \u0219i cu ma\u0219in\u0103ria celular\u0103.<\/p>\n<hr \/>\n<h2>2. Mecanisme de Ac\u021biune: Cum Amplific\u0103 Hipertermia Tratamentele Oncologice?<\/h2>\n<p>Eficien\u021ba clinic\u0103 superioar\u0103 a terapiei combinate este rezultatul sinergiei biologice robuste, care vizeaz\u0103 rezisten\u021ba tumorii la multiple niveluri.<\/p>\n<h3>2.1. Radiosensibilizarea: Dep\u0103\u0219irea Rezisten\u021bei Tumorale \u0219i Repar\u0103rii ADN-ului<\/h3>\n<p>Hipertermia este recunoscut\u0103 ca un radiosensibilizator puternic, abord\u00e2nd dou\u0103 dintre cele mai semnificative surse de e\u0219ec al radioterapiei:<\/p>\n<ol>\n<li><strong>Inhibarea Repar\u0103rii ADN-ului:<\/strong> HT inhib\u0103 mecanismele de reparare a ADN-ului deteriorate de radia\u021bii, asigur\u00e2nd o moarte celular\u0103 mai eficient\u0103 \u0219i ireversibil\u0103.<\/li>\n<li><strong>Oxigenarea Microambientului:<\/strong> HT cre\u0219te fluxul sanguin \u0219i \u00eembun\u0103t\u0103\u021be\u0219te oxigenarea tumoral\u0103, reduc\u00e2nd frac\u021biunea hipoxic\u0103 (rezistent\u0103 la radia\u021bii).<\/li>\n<\/ol>\n<p>Aceast\u0103 modificare func\u021bional\u0103 a microambientului tumoral face ca celulele canceroase, anterior rezistente, s\u0103 devin\u0103 mult mai sensibile la iradierea conven\u021bional\u0103. Aceast\u0103 modificare a microcircula\u021biei este un factor determinant care st\u0103 la baza <strong>ratelor ridicate de control loco-regional \u0219i CR documentate \u00een regimurile de chimioradioterapie cu hipertermie (CCRT+HT) pentru tumori ca cele de col uterin (LACC) \u0219i cap \u0219i g\u00e2t (HNC)<\/strong>.<\/p>\n<h3>2.2. Chimiosensibilizarea: \u00cembun\u0103t\u0103\u021birea Traficului \u0219i a Absorb\u021biei Celulare a Medicamentului<\/h3>\n<h4>2.2.1. Sinergie \u0219i Aditivitate cu Agen\u021bii Cheie<\/h4>\n<p>HT demonstreaz\u0103 efecte sinergice puternice cu anumite clase de chimioterapice esen\u021biale \u00een oncologie. \u00cen special, HT ac\u021bioneaz\u0103 sinergic cu agen\u021bii pe baz\u0103 de platin\u0103 (Cisplatin, Carboplatin) \u0219i Mitomycin C. Ace\u0219ti agen\u021bi sunt utiliza\u021bi frecvent \u00een indica\u021biile majore de Faz\u0103 III, cum ar fi cancerul de col uterin \u0219i tumorile ORL, suger\u00e2nd c\u0103 beneficiul observat \u00een studii este dependent de o asociere biologic\u0103 complementar\u0103, nu doar de c\u0103ldur\u0103. HT are, de asemenea, efecte aditive cu agen\u021bi precum Doxorubicin, Ciclofosfamid\u0103 \u0219i Gemcitabin\u0103.<\/p>\n<h4>2.2.2. Amplificarea Farmacocinetic\u0103<\/h4>\n<p>HT optimizeaz\u0103 livrarea medicamentului la nivelul tumorii prin cre\u0219terea traficului de medicamente \u00een tumori \u0219i nodulii limfatici (LN). Acest efect este atribuit cre\u0219terii perfuziei (fluxului sanguin) indus\u0103 de HT \u0219i modific\u0103rii permeabilit\u0103\u021bii membranei celulare. \u00cen cazul mHT, mecanismul de \u00eenc\u0103lzire localizat\u0103 la nivelul membranei celulare, facilitat de pierderea dielectric\u0103 mare, poate amplifica absorb\u021bia intracelular\u0103 a agen\u021bilor chimioterapici.<\/p>\n<h3>2.3. Imunomodularea: Transformarea unei Tumori \u201eReci\u201d \u00eentr-o Tumoare \u201eFierbinte\u201d (Imunogen\u0103)<\/h3>\n<p>Un mecanism de ac\u021biune din ce \u00een ce mai recunoscut este capacitatea HT de a modula r\u0103spunsul imun antitumoral, transform\u00e2nd efectiv tumori imunologic \"reci\" \u00een tumori \"fierbin\u021bi\" (inflamate).<\/p>\n<p>HT ac\u021bioneaz\u0103 ca un \"vaccin tumoral in situ\" prin inducerea eliber\u0103rii de Proteine de \u0218oc Termic (HSP) \u0219i de antigene tumorale. HSP-urile, cum ar fi HSP70, ac\u021bioneaz\u0103 ca semnale de pericol \u0219i faciliteaz\u0103 preluarea antigenelor de c\u0103tre celulele dendritice (DC). Odat\u0103 preluate, DC-urile migreaz\u0103 c\u0103tre ganglionii limfatici (LN), unde activeaz\u0103 \u0219i amorseaz\u0103 celulele T CD8+ citotoxice. Acest proces imunomodulator duce la o cre\u0219tere a lizei celulelor canceroase de c\u0103tre celulele Natural Killer (NK) \u0219i celulele T CD8+. De asemenea, HT \u00eembun\u0103t\u0103\u021be\u0219te exprimarea moleculelor de adeziune celular\u0103 (CAM), facilit\u00e2nd traficul limfocitar la locul tumorii.<\/p>\n<p>Tabelul 1 sintetizeaz\u0103 interac\u021biunile mecanistice ale hipertermiei cu tratamentele oncologice standard.<\/p>\n<p><strong>Tabelul 1: Mecanismele de Interac\u021biune ale Hipertermiei cu Terapiile Oncologice Standard<\/strong><\/p>\n<p>Tabelul 1: Indica\u021bii Emergente, QoL \u0219i Date de Faz\u0103 II\/Observa\u021bionale (Endpoint-uri Cheie)<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Mecanism \u021aint\u0103<\/strong><\/td>\n<td width=\"104\"><strong>Efect Biologic (39 C - 45 C)<\/strong><\/td>\n<td width=\"104\"><strong>Sinergie Terapeutic\u0103<\/strong><\/td>\n<td width=\"104\"><strong>Agen\u021bi Sinergici<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Inhibi\u021bia Repar\u0103rii ADN-ului<\/td>\n<td width=\"104\">Inhib\u0103 mecanismele de reparare a ADN-ului;<\/td>\n<td width=\"104\">Sensibilizeaz\u0103 celulele \u00een faza S<br \/>\nRadiosensibilizator Puternic (Complementeaz\u0103 RT)<\/td>\n<td width=\"104\">Radioterapia (RT)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Microambientul Tumoral<\/td>\n<td width=\"104\">Cre\u0219te fluxul sanguin, \u00eembun\u0103t\u0103\u021be\u0219te oxigenarea tumoral\u0103, cre\u0219te vasculariza\u021bia<\/td>\n<td width=\"104\">Amplific\u0103 eficacitatea RT; \u00cembun\u0103t\u0103\u021be\u0219te traficul medicamentelor (Chimiosemsibilizator)<\/td>\n<td width=\"104\">RT, Cisplatin, Mitomycin C<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Membrana Celular\u0103\/Structur\u0103<\/td>\n<td width=\"104\">Pierdere dielectric\u0103 crescut\u0103;<br \/>\nSemnalizare apoptotic\u0103 direct\u0103<\/td>\n<td width=\"104\">Absorb\u021bie \u00eembun\u0103t\u0103\u021bit\u0103 a medicamentului;<\/td>\n<td width=\"104\">Cisplatin, Carboplatin, Bleomycin<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Sistemul Imunitar<\/td>\n<td width=\"104\">Eliberarea de HSP-uri, activarea DC, amorsarea celulelor T, upregulare liza de c\u0103tre celulele NK\/CD8+ T<\/td>\n<td width=\"104\">Imunomodulator Tumoral; Imunitate Antitumoral\u0103 Amplificat\u0103<\/td>\n<td width=\"104\">Imunoterapie, RT, CHT<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_11120\" aria-describedby=\"caption-attachment-11120\" style=\"width: 747px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-11120\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg\" alt=\"mecanisme biologice hipertermie\" width=\"747\" height=\"412\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie.jpg 747w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/mecanisme-biologice-hipertermie-300x165.jpg 300w\" sizes=\"auto, (max-width: 747px) 100vw, 747px\" \/><figcaption id=\"caption-attachment-11120\" class=\"wp-caption-text\">mecanisme biologice hipertermie<\/figcaption><\/figure>\n<h2>3. Sinteza Dovezilor de Nivel 1A: Rezultatele Meta-Analizelor \u0219i Datelor Agregate<\/h2>\n<p>Evaluarea robust\u0103 a HT se bazeaz\u0103 pe analiza colectiv\u0103 a studiilor de Faz\u0103 III.<strong> O sintez\u0103 a dovezilor de Nivel 1A confirm\u0103 un beneficiu clinic generalizat pentru HT ad\u0103ugat\u0103 la terapia standard \u00een multiple categorii de tumori.<\/strong><\/p>\n<h3>3.1. Prezentare General\u0103 a Concluziilor Meta-Analitice<\/h3>\n<p><strong>O analiz\u0103 recent\u0103 a eficacit\u0103\u021bii HT, care a inclus 12 studii de Faz\u0103 III, a identificat \u0219ase studii de HT local-regional\u0103 \u0219i \u0219ase studii care includ Chimioterapia Intraperitoneal\u0103 Hipertermic\u0103 (HIPEC)[2]. Dintre acestea, cinci din cele \u0219ase studii de HT local-regional\u0103 au demonstrat o Supravie\u021buire Global\u0103 (OS) crescut\u0103 \u0219i\/sau o Rat\u0103 de R\u0103spuns Complet (CR) \u00eembun\u0103t\u0103\u021bit\u0103 prin ad\u0103ugarea HT la chimioterapia \u0219i\/sau radioterapia standard[2]. Acest lucru stabile\u0219te un consens \u0219tiin\u021bific solid care sus\u021bine utilizarea HT ca adjuvant de Nivel 1A pentru o gam\u0103 larg\u0103 de localiz\u0103ri tumorale loco-regionale.<\/strong><\/p>\n<h3>3.2. C\u00e2\u0219tiguri Cvantificabile: Supravie\u021buirea Global\u0103 (OS), R\u0103spunsul Complet (CR) \u0219i Controlul Local<\/h3>\n<p>Beneficiile clinice ale HT sunt cuantificabile pe endpoint-uri oncologice critice. Datele agregate pentru <strong>Cancerul de Col Uterin Avansat Local (LACC)<\/strong> demonstreaz\u0103:<\/p>\n<ul>\n<li><strong>R\u0103spunsul Complet (CR):<\/strong> Rata CR cre\u0219te semnificativ prin ad\u0103ugarea HT (Risc Relativ - <strong>RR de 0.56<\/strong>, CI 95% 0.39 la 0.79; <strong>p &lt; 0.001<\/strong>).<\/li>\n<li><strong>Controlul Recuren\u021bei Locale:<\/strong> HT reduce semnificativ Rata de Recuren\u021b\u0103 Local\u0103 (Raport de Risc - <strong>HR de 0.48<\/strong>, CI 95% 0.37 la 0.63; <strong>p &lt; 0.001<\/strong>).<\/li>\n<li><strong>Supravie\u021buirea Global\u0103 (OS):<\/strong> Tratamentul multimodal cu HT confer\u0103 o OS mai bun\u0103 (HR de <strong>67<\/strong>, CI 95% 0.45 la 0.99; <strong>p = 0.05<\/strong>).<\/li>\n<\/ul>\n<h2><\/h2>\n<h2>4. Analiza Studiilor de Faz\u0103 III Specifice pe tip cancer<\/h2>\n<p>Aceast\u0103 analiz\u0103 detaliat\u0103 examineaz\u0103 acele <strong>localiz\u0103ri tumorale unde HT este sus\u021binut\u0103 de studii clinice randomizate de cel mai \u00eenalt calibru, concentr\u00e2ndu-se pe rezultatele primare de supravie\u021buire \u0219i r\u0103spuns <\/strong>.<\/p>\n<h3><\/h3>\n<h3>4.1. Sarcomul de \u021aesuturi Moi (STS)<\/h3>\n<p>Sarcomul de \u021besuturi moi este una dintre indica\u021biile de referin\u021b\u0103 pentru integrarea HT, sus\u021binut\u0103 de studii de Faz\u0103 III. Trialurile care au comparat chimioterapia neoadjuvant\u0103 standard cu chimioterapia neoadjuvant\u0103 plus hipertermia regional\u0103 (RHT) au demonstrat c\u0103 <strong>ad\u0103ugarea HT a condus la o supravie\u021buire crescut\u0103 \u0219i la o \u00eembun\u0103t\u0103\u021bire a supravie\u021buirii f\u0103r\u0103 progresie local\u0103 (LPFS).<\/strong><br \/>\n\u00cen contextul sarcomului de risc \u00eenalt localizat, pentru pacien\u021bii candida\u021bi la tratament neoadjuvant, includerea RHT este justificat\u0103 pe baza rezultatelor \u00eembun\u0103t\u0103\u021bite de supravie\u021buire.Mai mult, analiza transla\u021bional\u0103 a acestor studii a dezv\u0103luit un mecanism imunologic important. S-a demonstrat c\u0103 terapia preoperatorie combinat\u0103 cu RHT transform\u0103 tumora, care la baz\u0103 era non-inflamat\u0103, \u00eentr-o tumor\u0103 inflamat\u0103. Aceast\u0103 reprogramare a microambientului tumoral permite o activitate imun\u0103 antitumoral\u0103 sporit\u0103. Acest efect indic\u0103 faptul c\u0103 beneficiul pe termen lung \u00een supravie\u021buire nu se datoreaz\u0103 doar sensibiliz\u0103rii directe la chimioterapie, ci \u0219i unei prime imunologice robuste, pozi\u021bion\u00e2nd HT ca un instrument valoros de modulare a microambientului.<\/p>\n<p>&nbsp;<\/p>\n<h3>4.2. Cancerul Ginecologic: Cancerul de Col Uterin Avansat Local (LACC)<\/h3>\n<p>Dovada pentru HT \u00een LACC, ad\u0103ugat\u0103 la chimioradioterapia concomitent\u0103 (CCRT), este printre cele mai conving\u0103toare din oncologie.<\/p>\n<h4>4.2.1. Consensul Studiilor (CR \u0219i Recuren\u021ba Local\u0103)<\/h4>\n<p>Sistematic, meta-analizele \u0219i datele agregate din studii randomizate confirm\u0103 avantajul terapiei tri-modale (CCRT + HT).<strong> O analiz\u0103 a datelor agregate a ar\u0103tat o rat\u0103 de r\u0103spuns complet (CR) semnificativ mai mare (RR 0.56; p &lt; 0.001) \u0219i o rat\u0103 redus\u0103 a recuren\u021bei locale (HR 0.48; p &lt; 0.001) cu tratamentul combinat. Acest control loco-regional superior a f\u0103cut din tri-modality treatment o abordare fezabil\u0103 \u0219i eficient\u0103.<\/strong><\/p>\n<h4>4.2.2. Cvantificarea Supravie\u021buirii Globale (OS)<\/h4>\n<p><strong>Supravie\u021buirea Global\u0103 OS a fost semnificativ \u00eembun\u0103t\u0103\u021bit\u0103 prin asocierea CCRT cu HT, cu un HR de 0.67 (CI 95% 0.45 la 0.99; p = 0.05).<\/strong><br \/>\nDe\u0219i datele istorice trebuie interpretate \u00een contextul standardelor terapeutice actuale, un studiu de Faz\u0103 III din Italia care a evaluat RT +- HT pentru ganglionii limfatici cervicali scuamo\u0219i N3 din acea er\u0103 a demonstrat o diferen\u021b\u0103 izbitoare: <strong>Rata CR \u00een lotul pacienti ce au primit tratament combinat a fost de 82.3% fa\u021b\u0103 de 36.8% \u00een lotul pacienti oncologici tratati\u00a0 doar cu radioterapie<\/strong>. O analiz\u0103 pe termen lung a aceluia\u0219i studiu a raportat <strong>o Supravie\u021buire Global\u0103 la 5 ani de 55% fa\u021b\u0103 de 0% \u00een bra\u021bul cu hipertermie versus bra\u021bul tratat doar cu radia\u021bii[3,4]<\/strong>. De\u0219i regimul de control (RT monoterapie) este considerat inferior dup\u0103 standardele moderne (care utilizeaz\u0103 CCRT), aceste rezultate istorice r\u0103m\u00e2n extrem de valoroase, demonstr\u00e2nd capacitatea extraordinar\u0103 de radiosensibilizare a HT, \u00een special \u00een boala nodal\u0103 cu volum mare, care este de obicei foarte hipoxic\u0103 \u0219i rezistent\u0103 la terapie.<\/p>\n<h4>4.2.3. Dovezi aditionale(OS)<\/h4>\n<p>Cel mai puternic nivel de dovezi adi\u021bionale este oferit de <strong>Cancerul de Col Uterin (Cervix)<\/strong>, unde Hipertermia loco-regional\u0103 combinat\u0103 cu Radioterapia (RT) sau Chimio-Radioterapia (CTRT) a fost studiat\u0103 \u00een numeroase studii randomizate.<\/p>\n<p>Aceste rezultate (dovezi de nivel inalt pentru cancerul de cervix) sunt extrase din meta-analize care compar\u0103 tratamentul standard (RT sau CTRT) cu tratamentul combinat (RT\/CTRT + Hipertermie):<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"208\">Indicator Clinic<\/td>\n<td width=\"208\">Rezultat Ob\u021binut cu RT + Hipertermie<\/td>\n<td width=\"208\">Referin\u021b\u0103 (Revizuirile Citite)<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"208\"><strong>R\u0103spuns Complet (CR)<\/strong><\/td>\n<td width=\"208\">\u00cembun\u0103t\u0103\u021bire constant\u0103 a ratei de CR: <strong>+22.1%<\/strong> fa\u021b\u0103 de RT simpl\u0103.<\/td>\n<td width=\"208\">Meta-analize<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Control Loco-Regional (LRC)<\/strong><\/td>\n<td width=\"208\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103: <strong>+23.1%<\/strong> fa\u021b\u0103 de RT simpl\u0103.<\/td>\n<td width=\"208\">Meta-analize<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Supravie\u021buirea Global\u0103 (OS)<\/strong><\/td>\n<td width=\"208\">S-a observat o \u00eembun\u0103t\u0103\u021bire a supravie\u021buirii globale (OS) pe termen lung (HR 0.67; p = 0.03) cu ad\u0103ugarea Hipertermiei.<\/td>\n<td width=\"208\">Meta-analiz\u0103 actualizat\u0103<\/td>\n<\/tr>\n<tr>\n<td width=\"208\"><strong>Supravie\u021buirea f\u0103r\u0103 Boal\u0103 (DFS)<\/strong><\/td>\n<td width=\"208\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 a DFS pe 2 \u0219i 3 ani \u00een cazul combin\u0103rii cu CTRT.<\/td>\n<td width=\"208\">Studii randomizate de faz\u0103 III<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p>Iat\u0103 cele trei meta-analize \u0219i studiul de Faz\u0103 III la care s-a f\u0103cut referire, \u00eempreun\u0103 cu link-urile corespunz\u0103toare:<\/p>\n<h5>4.2.3.1. Meta-analiz\u0103: CR, Control Loco-Regional (LRC) \u0219i Supravie\u021buire Global\u0103 (OS) (Lutgens et al.)<\/h5>\n<p>Acesta este considerat un studiu fundamental (Cochrane Review) care a sintetizat rezultatele a multiple trialuri randomizate, confirm\u00e2nd beneficiul major al ad\u0103ug\u0103rii Hipertermiei.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Indicatori confirma\u021bi<\/td>\n<td width=\"312\">Rezultat cheie<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>R\u0103spuns Complet (CR)<\/strong><\/td>\n<td width=\"312\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 (RR 0.56; p &lt; 0.001)<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Control Loco-Regional (LRC)<\/strong><\/td>\n<td width=\"312\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 (HR 0.48; p &lt; 0.001)<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Supravie\u021buire Global\u0103 (OS)<\/strong><\/td>\n<td width=\"312\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 la 3 ani (HR 0.67; p = 0.05)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titlu:<\/strong> Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma<\/li>\n<li><strong>Autori:<\/strong> Lutgens L, van der Zee J, Pijls-Johannesma M, et al.<\/li>\n<li><strong>Link PubMed (Actualizare 2010):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/20091593\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.2. Meta-analiz\u0103 \u00een Re\u021bea (NMA): Cele mai bune strategii (Datta et al. 2019)<\/h5>\n<p>Acest studiu a folosit o metod\u0103 avansat\u0103 (Network Meta-Analysis) pentru a compara Hipertermia cu alte 13 interven\u021bii terapeutice, clasific\u00e2nd-o printre op\u021biunile de top.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Indicatori confirma\u021bi<\/td>\n<td width=\"312\">Rezultat cheie<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Clasamentul Tratamentelor<\/strong><\/td>\n<td width=\"312\"><strong>RT+HT<\/strong> \u0219i <strong>CTRT+HT<\/strong> s-au clasat printre primele trei interven\u021bii cu cel mai bun impact cuprinz\u0103tor asupra LRC, OS \u0219i toxicitate.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titlu:<\/strong> Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials<\/li>\n<li><strong>Autori:<\/strong> Datta NR, Stutz E, Gomez S, Bodis S.<\/li>\n<li><strong>Link PubMed:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/30391522\/<\/a><\/li>\n<\/ul>\n<h5>4.2.3.3. Studiu de Faz\u0103 III: Supravie\u021buirea F\u0103r\u0103 Boal\u0103 (DFS) \u0219i QoL cu mEHT<\/h5>\n<p>Acesta este unul dintre studiile de Faz\u0103 III mai recente care confirm\u0103 beneficii precum DFS \u0219i \u00eembun\u0103t\u0103\u021birea Calit\u0103\u021bii Vie\u021bii (QoL) cu o tehnic\u0103 modern\u0103 de Hipertermie (mEHT) ad\u0103ugat\u0103 la Chimio-Radioterapie (CTRT).<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"312\">Indicatori confirma\u021bi<\/td>\n<td width=\"312\">Rezultat cheie<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"312\"><strong>Supravie\u021buirea F\u0103r\u0103 Boal\u0103 (DFS)<\/strong><\/td>\n<td width=\"312\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 a DFS pe 2 \u0219i 3 ani cu ad\u0103ugarea mEHT la CTRT.<\/td>\n<\/tr>\n<tr>\n<td width=\"312\"><strong>Calitatea Vie\u021bii (QoL)<\/strong><\/td>\n<td width=\"312\">\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 a QoL, f\u0103r\u0103 a cre\u0219te toxicitatea.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Titlu:<\/strong> Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients<\/li>\n<li><strong>Autori:<\/strong> Minnaar CA, Maposa I, Kotzen JA, et al.<\/li>\n<li><strong>Link MDPI (Text integral disponibil):<\/strong> <a href=\"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/14\/3\/656<\/a><\/li>\n<\/ul>\n<p>Pentru cancerul de col uterin avansat loco-regional, ad\u0103ugarea Hipertermiei loco-regionale nu doar cre\u0219te \u0219ansele de eradicare local\u0103 a tumorii (CR), dar are \u0219i un impact pozitiv semnificativ asupra supravie\u021buirii pe termen lung (OS \u0219i DFS).<\/p>\n<h3>4.3. Cancerele Capului \u0219i G\u00e2tului (HNC)<\/h3>\n<p>Hipertermia local-regional\u0103 este un tratament de Nivel 1A pentru diverse tumori ale capului \u0219i g\u00e2tului, inclusiv recuren\u021be \u0219i boal\u0103 avansat\u0103, unde controlul local are un impact direct asupra calit\u0103\u021bii vie\u021bii \u0219i a supravie\u021buirii.<\/p>\n<h4>4.3.1. Datele Studiilor Randomizate de Faz\u0103 III<\/h4>\n<p><strong>Studiile randomizate \u0219i prospective de Faz\u0103 III au documentat beneficii clare pentru asocierea chimioradioterapiei (CRT) cu HT fa\u021b\u0103 de CRT singur\u0103 \u00een cancerul nazofaringian (NPC).<\/strong><br \/>\n\u25cf <strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Kang 2013<\/a> (NPC):<\/strong> Acest studiu de Faz\u0103 III a raportat o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103. <strong>Supravie\u021buirea F\u0103r\u0103 Boal\u0103 (DFS) la 5 ani a crescut de la 25.5% la 51.3% (p &lt; 0.005), iar OS la 5 ani a crescut de la 50% la 68.4% (p &lt; 0.005). Rata CR a crescut, de asemenea, de la 62.8% la 81.6%<\/strong>.<br \/>\n\u25cf <strong><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\">Huilgol 2010<\/a> (Cavitatea Oral\u0103\/Orofaringe\/Hipofaringe):<\/strong> R\u0103spunsul complet a fost observat la<strong> 42,4% din grupul tratat doar cu radioterapie, comparativ cu 78,6% \u00een grupul tratat cu HT<\/strong>. Diferen\u021ba a fost semnificativ\u0103 statistic (&lt; 0,05). Analiza Kaplan-Meir a supravie\u021buirii a ar\u0103tat, de asemenea, o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 \u00een favoarea radioterapiei-HT. Nu s-au \u00eenregistrat arsuri termice care limiteaz\u0103 doza \u0219i toxicitate excesiv\u0103 la nivelul mucoaselor sau termic\u0103.<\/p>\n<p>C\u00e2\u0219tigurile substan\u021biale \u0219i constante \u00een DFS \u0219i OS \u00een HNC, unde ratele de recidiv\u0103 local\u0103 sunt adesea ridicate, subliniaz\u0103 faptul c\u0103 HT este eficient\u0103 \u00een dep\u0103\u0219irea radiorezisten\u021bei locale, devenind o component\u0103 esen\u021bial\u0103 a tratamentului cu inten\u021bie curativ\u0103[5].<\/p>\n<h3>4.4. Cancere Gastrointestinale: Cancerul Rectal \u0219i Anal<\/h3>\n<p>Integrarea HT cu chimioradioterapia neoadjuvant\u0103 (CRT) \u00een cancerul rectal avansat local a demonstrat beneficii critice \u00een controlul loco-regional \u0219i supravie\u021buire.<\/p>\n<h4>4.4.1. Rezultatele Fazei III \u00een Cancerul Rectal<\/h4>\n<p>Studiul prospectiv randomizat <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong>Ott 2019<\/strong> <\/a>a comparat CRT cu CRT + HT \u0219i a raportat \u00eembun\u0103t\u0103\u021biri semnificative la 5 ani \u00een bra\u021bul cu HT :<br \/>\n<strong>\u25cf Supravie\u021buirea Global\u0103 (OS): 95.8% vs. 74.5% (P = 0.045).<\/strong><br \/>\n<strong>\u25cf Supravie\u021buirea F\u0103r\u0103 Boal\u0103 (DFS): 89.1% vs. 70.4% (P = 0.027).<\/strong><br \/>\n<strong>\u25cf Supravie\u021buirea F\u0103r\u0103 Recuren\u021b\u0103 Local\u0103 (LRFS): 97.7% vs. 78.7% (P = 0.006)<\/strong>.<\/p>\n<h4>4.4.2. R\u0103spunsul Patologic \u0219i Implica\u021biile Clinice<\/h4>\n<p>Rata de R\u0103spuns Patologic Complet (pCR) a fost, de asemenea, \u00eembun\u0103t\u0103\u021bit\u0103 prin ad\u0103ugarea HT<strong>, o meta-analiz\u0103 ar\u0103t\u00e2nd o cre\u0219tere de la 16% (CRT) la 22.5% (CRT+HT, p = 0.043).<\/strong><br \/>\n<strong>Cel mai important, rata superioar\u0103 a LRFS (97.7%) \u0219i \u00eembun\u0103t\u0103\u021birea ratelor de supravie\u021buire f\u0103r\u0103 colostomie (87.7% vs. 69.0%, P = 0.016) eviden\u021biaz\u0103 rolul HT nu numai \u00een sterlizarea tumoral\u0103 local\u0103, ci \u0219i \u00een strategiile de prezervare a sfincterului.<\/strong><\/p>\n<p>&nbsp;<\/p>\n<h3>4.5. Melanomul Malign (Boala Loco-regional\u0103)<\/h3>\n<p><strong>Cercet\u0103rile fundamentale de Faz\u0103 III (<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">Overgaard et al., 1995<\/a>) au demonstrat c\u0103 asocierea radioterapiei cu HT \u00eembun\u0103t\u0103\u021be\u0219te Rata de R\u0103spuns Complet \u0219i OS \u00een melanomul avansat.<\/strong><\/p>\n<p><strong>Rezultate Cheie: RT + Hipertermie vs. Radioterapie<\/strong><\/p>\n<p>Studiul multicentric european a repartizat aleatoriu 134 de leziuni metastatice sau recurente de melanom la 70 de pacien\u021bi, pentru a primi fie radioterapie singur\u0103, fie radioterapie urmat\u0103 de hipertermie (43\u00b0C timp de 60 de minute).<\/p>\n<h5>1. Controlul Local al Tumorii (Endpoint-ul Principal)<\/h5>\n<p>Cel mai important rezultat a fost \u00eembun\u0103t\u0103\u021birea semnificativ\u0103 a controlului local al tumorii pe termen lung.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"156\">Endpoint<\/td>\n<td width=\"156\">Radioterapie Singur\u0103 (RT)<\/td>\n<td width=\"156\">Radioterapie + Hipertermie (RT + HT)<\/td>\n<td width=\"156\">Diferen\u021b\u0103 Cheie<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"156\"><strong>Controlul Local Actuarial la 2 Ani<\/strong><\/td>\n<td width=\"156\"><strong>28%<\/strong><\/td>\n<td width=\"156\"><strong>46%<\/strong><\/td>\n<td width=\"156\"><strong>\u00cembun\u0103t\u0103\u021bire semnificativ\u0103 (p = 0.008)<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Concluzie:<\/strong> Ad\u0103ugarea HT a \u00eembun\u0103t\u0103\u021bit controlul local al tumorii cu <strong>18 puncte procentuale<\/strong> la 2 ani.<\/li>\n<\/ul>\n<h5>2. Analiza Multivariat\u0103 (Factorii Prognostici)<\/h5>\n<p>Analiza de regresie Cox multivariat\u0103 a confirmat c\u0103 <strong>hipertermia<\/strong> a fost cel mai important factor prognostic pentru controlul local la 2 ani.<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"208\">Variabil\u0103 Prognostic\u0103<\/td>\n<td width=\"208\">Risc (Odds Ratio)<\/td>\n<td width=\"208\">Valoare P<\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"208\"><strong>Hipertermia<\/strong><\/td>\n<td width=\"208\"><strong>1.73<\/strong> (pentru control local)<\/td>\n<td width=\"208\"><strong>p = 0.023<\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"208\">Doza de Radia\u021bii<\/td>\n<td width=\"208\">1.17<\/td>\n<td width=\"208\">p = 0.05<\/td>\n<\/tr>\n<tr>\n<td width=\"208\">Dimensiunea Tumorii<\/td>\n<td width=\"208\">0.91<\/td>\n<td width=\"208\">p = 0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>Concluzie:<\/strong> Aceasta demonstreaz\u0103 c\u0103 beneficiul adus de HT este independent \u0219i cel pu\u021bin la fel de important ca doza de radia\u021bii utilizat\u0103 \u0219i dimensiunea tumorii.<\/li>\n<\/ul>\n<h5>3. Supravie\u021buirea (Local Control is Curative)<\/h5>\n<p>Studiul a observat o leg\u0103tur\u0103 puternic\u0103 \u00eentre controlul local de succes \u0219i supravie\u021buirea pe termen lung:<\/p>\n<ul>\n<li><strong>Supravie\u021buirea Global\u0103 la 5 ani:<\/strong> Rata general\u0103 a fost de 19%.<\/li>\n<li><strong>Supravie\u021buirea la 5 ani pentru pacien\u021bii cu boal\u0103 complet controlat\u0103:<\/strong> A crescut la <strong>38%<\/strong>.<\/li>\n<li><strong>Concluzie:<\/strong> Controlul local reu\u0219it al unei singure leziuni sau al c\u00e2torva leziuni metastatice a avut un <strong>poten\u021bial curativ semnificativ<\/strong>, subliniind importan\u021ba eficacit\u0103\u021bii locale sporite de HT.<\/li>\n<\/ul>\n<h5>4. Toxicitatea \u0219i Siguran\u021ba<\/h5>\n<ul>\n<li>Ad\u0103ugarea c\u0103ldurii <strong>nu a crescut \u00een mod semnificativ reac\u021biile acute sau tardive<\/strong> la radia\u021bii.<\/li>\n<li>Tratamentul cu \u00eenc\u0103lzire a fost \u00een general <strong>bine tolerat<\/strong>.<\/li>\n<\/ul>\n<p><strong>Not\u0103:<\/strong> Studiul a men\u021bionat dificult\u0103\u021bi \u00een atingerea obiectivului de protocol termic (43\u00b0C), reu\u0219ind acest lucru doar \u00een 14% din tratamente, ceea ce sugereaz\u0103 c\u0103 beneficiul real ar putea fi chiar mai mare cu protocoale de \u00eenc\u0103lzire optimizate.<\/p>\n<p>Av\u00e2nd \u00een vedere c\u0103 melanomul este o boal\u0103 extrem de imunogen\u0103 \u0219i a fost printre primele \u021binte ale imunoterapiei, capacitatea dovedit\u0103 a HT de a induce un r\u0103spuns imun antitumoral \u0219i de a spori controlul local deschide oportunit\u0103\u021bi clinice semnificative pentru integrarea cu noii agen\u021bi imuno-oncologici, amplific\u00e2nd astfel eficacitatea blocan\u021bilor punctelor de control.[4]<\/p>\n<h3>4.6 Cancer san recurent<\/h3>\n<h4>4.6.1.Meta-analiza care confirm\u0103 eficacitatea termoradioterapiei \u00een cancerul de s\u00e2n recurent<\/h4>\n<p>O meta-analiza consolideaz\u0103 datele din studiile clinice de faz\u0103 III, demonstr\u00e2nd rata de r\u0103spuns complet (CR) men\u021bionat\u0103 pentru terapia combinat\u0103 (Radioterapie + Hipertermie) \u00een cazul <strong>cancerului de s\u00e2n recurent loco-regional (LRBC)<\/strong>.<\/p>\n<p>Acesta este studiul care sus\u021bine concluziile de Nivel 1A de eviden\u021b\u0103, incluz\u00e2nd ratele de <strong>60-66% CR<\/strong> pentru tratamentul combinat:<\/p>\n<p><strong>Studiul:<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis.<\/strong><\/a><\/p>\n<ul>\n<li><strong>Autori:<\/strong> Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S.<\/li>\n<li><strong>Pub licat \u00een:<\/strong> <em>International Journal of Radiation Oncology Biology Physics<\/em>, 2016.<\/li>\n<li><strong>Concluzie:<\/strong> Termoradioterapia (RT + Hipertermie) cre\u0219te rata de r\u0103spuns complet (CR) cu aproximativ <strong>22%<\/strong> comparativ cu radioterapia singur\u0103; in studiile care au comparat cele dou\u0103 bra\u021be de tratament, s-a ob\u021binut o rat\u0103 a R\u0103spunsului Complet (CR) de <strong>60.2%<\/strong> cu RT + Hipertermie (HT), comparativ cu 38.1% doar cu RT (Radioterapie).ajung\u00e2nd la o rat\u0103 de CR de\u00a0<strong>66.6%<\/strong> \u00een cazul re-iradierei cu hipertermie.<\/li>\n<\/ul>\n<h4>4.6.2 Recuren\u021ba Toracic\u0103 a Cancerului de S\u00e2n<\/h4>\n<p>Hipertermia, de obicei \u00een combina\u021bie cu RT, are dovezi de Nivel 1A pentru tratamentul recuren\u021bei toracice a cancerului de s\u00e2n.<br \/>\nAceast\u0103 combina\u021bie este deosebit de valoroas\u0103 \u00een contextul recidivei peretelui toracic, unde op\u021biunile de tratament sunt adesea limitate. Studiile arat\u0103 Rate de R\u0103spuns Complet (CR) ridicate, variind \u00eentre 40% \u0219i 86%, \u0219i Rate de Control Local (LC) \u00eentre 70% \u0219i 76% atunci c\u00e2nd RT este combinat\u0103 cu HT. \u00cen plus, ratele de OS la 5 ani pot ajunge p\u00e2n\u0103 la 50% pentru aceast\u0103 boal\u0103 recurent\u0103.<br \/>\nCombina\u021bia RT+HT ofer\u0103 o strategie local\u0103 eficient\u0103 pentru paliere \u0219i control pe termen lung, reduc\u00e2nd adesea necesitatea unei terapii de salvare cu doze mari sau a unei interven\u021bii chirurgicale radicale<\/p>\n<h4>4.6.3. Tendin\u021ba General\u0103 \u00een Terapia Loco-Regional\u0103 -Alte indica\u021bii oncologice cu dovezi de Nivel 1<\/h4>\n<p>Extinderea concluziilor la nivelul terapiilor loco-regionale:<\/p>\n<ul>\n<li><strong>Consolidarea dovezilor:<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">A doua recenzie sistematic\u0103<\/a>(<em>prima Hildenbrandt et al<\/em> )\u00a0arat\u0103 c\u0103 <strong>5 din 6 studii de Faz\u0103 III<\/strong> (care au vizat tumori superficiale \u0219i loco-regionale \u2013 inclusiv cancer de s\u00e2n, cap \u0219i g\u00e2t, melanom) au demonstrat o cre\u0219tere a <strong>Supravie\u021buirii Globale (OS)<\/strong> \u0219i\/sau a <strong>R\u0103spunsului Complet (CR)<\/strong> atunci c\u00e2nd Hipertermia a fost ad\u0103ugat\u0103 tratamentului standard.<\/li>\n<li><strong>Aplica\u021bii Paliative:<\/strong> Studiile men\u021bioneaz\u0103 c\u0103 Hipertermia, combinat\u0103 cu RT, a dus la o cre\u0219tere semnificativ\u0103 a <strong>R\u0103spunsului Complet la Dureri<\/strong> \u00een cazul metastazelor osoase dureroase, oferind o \u00eembun\u0103t\u0103\u021bire important\u0103 a Calit\u0103\u021bii Vie\u021bii (QoL) pacien\u021bilor.<\/li>\n<\/ul>\n<h3><\/h3>\n<h3>4.7. Cancerul Vezical: Chimioterapia Intravezical\u0103 Hipertermic\u0103 (HIVEC)<\/h3>\n<p>Hyperthermic Intravesical Chemotherapy (HIVEC) implic\u0103 utilizarea \u00eenc\u0103lzirii (tipic la 43 grade C) a Mitomycin C (MMC) \u00een timpul instil\u0103rii vezicale pentru cancerul vezical non-musculo-invaziv (NMIBC).[6]<\/p>\n<h4>4.7.1. Rezultatele Studiului de Faz\u0103 III HIVEC-1<\/h4>\n<p>Studiul HIVEC-1, un trial randomizat de Faz\u0103 3, a avut ca obiectiv compararea supravie\u021buirii f\u0103r\u0103 recuren\u021b\u0103 (RFS) cu MMC la normotermie fa\u021b\u0103 de MMC hipertermic (43\u00b0C timp de 30 sau 60 de minute) la pacien\u021bii cu NMIBC cu risc intermediar (IR-NMIBC)[6].<br \/>\nEndpoint-ul Primar (RFS): RFS la 24 de luni \u00een popula\u021bia Intention-to-Treat (ITT) a fost de 77% \u00een grupul de control (normotermie) fa\u021b\u0103 de 82% (HT 30 min) \u0219i 80% (HT 60 min). Concluzia studiului a fost c\u0103 HT nu a fost statistic superior fa\u021b\u0103 de MMC la normotermie pentru RFS la 24 de luni, cu un p de 0.6 [6].<br \/>\nImplica\u021bia Clinic\u0103: Lipsa de superioritate \u00een cazul IR-NMIBC sugereaz\u0103 c\u0103 popula\u021bia de risc intermediar ar putea s\u0103 nu beneficieze suficient de sinergia termic\u0103\/chimic\u0103, sau c\u0103 protocoalele termice specifice utilizate \u00een trial (de exemplu, durata fix\u0103) au fost sub-optime.<\/p>\n<h4>4.7.2. Nuan\u021be \u0219i Progresia F\u0103r\u0103 Boal\u0103<\/h4>\n<p>\u00cen contrast cu rezultatul RFS pentru IR-NMIBC, datele din alte studii eviden\u021biaz\u0103 un beneficiu pentru pacien\u021bii cu risc \u00eenalt, \u00een special cei care au e\u0219uat la terapia cu BCG. O analiz\u0103 a ar\u0103tat <strong>o Supravie\u021buire F\u0103r\u0103 Progresie (PFS) semnificativ mai bun\u0103 pentru HIVEC vs. BCG (95.7% vs 71.8%; p = 0.043) \u00een analiza ITT[7]<\/strong>. Un alt studiu a ar\u0103tat c\u0103, de\u0219i chimiotermia cu HIVEC a ob\u021binut o rat\u0103 RFS de 60% la 1 an \u0219i o rat\u0103 de prezervare a vezicii urinare de 92.4%, pentru pacien\u021bii cu risc foarte \u00eenalt care e\u0219ueaz\u0103 la BCG, cistectomia r\u0103m\u00e2ne standardul de \u00eengrijire, de\u0219i HIVEC poate fi o alternativ\u0103 pentru cei ineligibili pentru interven\u021bia chirurgical\u0103[8]. Aceasta confirm\u0103 faptul c\u0103 eficacitatea HT \u00een cancerul vezical depinde crucial de stratificarea pacientului.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Tabelul 2 sintetizeaz\u0103 rezultatele clinice cheie de Faz\u0103 III pentru integrarea hipertermiei.<\/strong><\/p>\n<p>Tabelul 2: Rezultatele Clinice Cheie de Faz\u0103 III pentru Hipertermie \u00een Oncologie (HT + \u00cengrijire Standard vs. \u00cengrijire Standard Singur\u0103)<\/p>\n<p>&nbsp;<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Tip de Cancer (Modalitatea HT)<\/strong><\/td>\n<td width=\"104\"><strong>Tip de Studiu\/Endpoint<\/strong><\/td>\n<td width=\"104\"><strong>HT + \u00cengrijire Standard<\/strong><\/td>\n<td width=\"104\"><strong>\u00cengrijire Standard monoterapie<\/strong><\/td>\n<td width=\"104\"><strong>Semnifica\u021bie Statistic\u0103\/Rezultat Endpoint<\/strong><\/td>\n<td width=\"104\"><strong>Referin\u021b\u0103<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Sarcom de \u021aesuturi Moi (L-R HT + CT) 11,3 ani<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (<\/p>\n<p>OS 5 ani<\/p>\n<p>&nbsp;<\/p>\n<p>OS 10 ani)<\/td>\n<td width=\"104\">62,7%<\/p>\n<p>&nbsp;<\/p>\n<p>52,6%<\/td>\n<td width=\"104\">\u00a051,3%<\/p>\n<p>&nbsp;<\/p>\n<p>42,7%<\/td>\n<td width=\"104\">Comparativ cu chimioterapia neoadjuvant\u0103 administrat\u0103 singur\u0103, ad\u0103ugarea hipertermiei regionale a \u00eembun\u0103t\u0103\u021bit <strong>supravie\u021buirea f\u0103r\u0103 progresia bolii DFS<\/strong> la nivel local (rata de risc [RR], 0,65; I\u00ce 95%, 0,49-0,86; P = 0,002).<\/p>\n<p>Pacien\u021bii randomiza\u021bi la chimioterapie plus hipertermie au avut <strong>rate de supravie\u021buire OS<\/strong> prelungite comparativ cu cei randomiza\u021bi la chimioterapie neoadjuvant\u0103 singur\u0103 (RR, 0,73; I\u00ce 95%, 0,54-0,98; P = 0,04), cu o supravie\u021buire la 5 ani de 62,7% (I\u00ce 95%, 55,2%-70,1%) fa\u021b\u0103 de 51,3% (I\u00ce 95%, 43,7%-59,0%), respectiv, \u0219i o supravie\u021buire la 10 ani de 52,6% (I\u00ce 95%, 44,7%-60,6%) fa\u021b\u0103 de 42,7% (I\u00ce 95%, 35,0%-50,4%).<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Col Uterin (LACC) (L-R HT + RT) 12 ani<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (<strong>OS la 12 ani<\/strong>)<\/td>\n<td width=\"104\">37%<\/td>\n<td width=\"104\">20%<\/td>\n<td width=\"104\">OS semnificativ mai bun\u0103 (P &lt; 0.05)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Rectal (CRT + HT) 5 ani<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat<\/p>\n<p>(<strong>OS la 5 ani<\/strong>,<\/p>\n<p>&nbsp;<\/p>\n<p>DFS 5 ani<\/p>\n<p>&nbsp;<\/p>\n<p>local recurrence-free LRF 5 ani<\/p>\n<p>&nbsp;<\/p>\n<p>colostomy-free survival rates CFSR 5 ani<\/p>\n<p>&nbsp;<\/td>\n<td width=\"104\">95.8%<\/p>\n<p>&nbsp;<\/p>\n<p>89.1<\/p>\n<p>&nbsp;<\/p>\n<p>97.7<\/p>\n<p>&nbsp;<\/p>\n<p>87.7<\/td>\n<td width=\"104\">74.5%<\/p>\n<p>&nbsp;<\/p>\n<p>70.4%<\/p>\n<p>&nbsp;<\/p>\n<p>78.7%<\/p>\n<p>&nbsp;<\/p>\n<p>69.0%<\/td>\n<td width=\"104\">OS \u00eembun\u0103t\u0103\u021bit\u0103 (P = 0.045)<\/p>\n<p>&nbsp;<\/p>\n<p>DFS \u00eembun\u0103t\u0103\u021bit\u0103 ( <i>P<\/i>\u202f=\u20090.027),<\/p>\n<p>&nbsp;<\/p>\n<p>LRF \u00eembun\u0103t\u0103\u021bit\u0103 ( <i>P<\/i>\u202f=\u20090.006),<\/p>\n<p>&nbsp;<\/p>\n<p>CFSR \u00eembun\u0103t\u0103\u021bit\u0103 ( <i>P<\/i>\u202f=\u20090.016))<\/p>\n<p>&nbsp;<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer cap si gat NPC (CRT + HT)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (DFS 5 ani<\/p>\n<p>si<\/p>\n<p>OS la 5 ani<\/p>\n<p>si<\/p>\n<p>CR )<\/td>\n<td width=\"104\">51,3%<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>68,4%<\/p>\n<p>&nbsp;<\/p>\n<p>81,6%<\/td>\n<td width=\"104\">25,5%<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>50%<\/p>\n<p>&nbsp;<\/p>\n<p>62,8%<\/td>\n<td width=\"104\">\u00a0Acest studiu de Faz\u0103 III a raportat o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103. .<\/td>\n<td width=\"104\"><strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\">Kang 2013<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer cap si gat <strong>Cavitatea Oral\u0103\/Orofaringe\/Hipofaringe <\/strong>(RT + HT)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (CR)<\/td>\n<td width=\"104\">78,6%<\/td>\n<td width=\"104\">42,4%<\/td>\n<td width=\"104\">\u00a0\u00a0Diferen\u021ba a fost semnificativ\u0103 statistic (&lt; 0,05). Analiza Kaplan-Meir a supravie\u021buirii a ar\u0103tat, de asemenea, o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 \u00een favoarea radioterapiei-HT. Nu s-au \u00eenregistrat arsuri termice care limiteaz\u0103 doza \u0219i toxicitate excesiv\u0103 la nivelul mucoaselor sau termic\u0103.<\/td>\n<td width=\"104\"><strong><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\">Huilgol 2010<\/a><\/strong><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Melanom Malign (RT + HT)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (CR)<\/td>\n<td width=\"104\">46%<\/td>\n<td width=\"104\">28%<\/td>\n<td width=\"104\">imbunatatire semnificativa Controlul Local Actuarial la 2 Ani (p = 0.008)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer S\u00e2n Recidivat (RT + HT) - HT inclusa in ghidurile NCCN<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (CR)<\/td>\n<td width=\"104\">60.2%<\/td>\n<td width=\"104\">38.1%<\/td>\n<td width=\"104\">Rat\u0103 CR crescut\u0103 cu 57% relativ<\/td>\n<td width=\"104\"><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Vezical IR NMI (HIVEC-1)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (RFS la 24 luni)<\/td>\n<td width=\"104\">80%-82%<\/td>\n<td width=\"104\">77%<\/td>\n<td width=\"104\">Nicio diferen\u021b\u0103 semnificativ\u0103 (p = 0.6)<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Metastaze Osoase (WBH + RT)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (CR la Durere)<\/td>\n<td width=\"104\">47.4%<\/td>\n<td width=\"104\">5.3%<\/td>\n<td width=\"104\">CR \u00eembun\u0103t\u0103\u021bit\u0103 (P &lt; 0.05); Timp de r\u0103spuns redus la 10 zile<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Metastaze Osoase (RF HT + RT)<\/td>\n<td width=\"104\">Faz\u0103 III Randomizat (CR la Durere)<\/td>\n<td width=\"104\">\u00a037,9%<\/p>\n<p>&nbsp;<\/p>\n<p>58,6%<\/td>\n<td width=\"104\">7,1%<\/p>\n<p>&nbsp;<\/p>\n<p>32,1%<\/td>\n<td width=\"104\">CR \u00eembun\u0103t\u0103\u021bit\u0103 la 3 luni (P = 0.006);<\/p>\n<p>CR acumulata \u00een decurs de 3 luni dup\u0103 tratament P=0,045);<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div id=\"IDtable-wrap-foot\" class=\"NLM_table-wrap-foot\">\n<div id=\"TF4\">\n<p class=\"first last\"><span dir=\"auto\">mEHT: electrohipertermie modulat\u0103; CT: chimioterapie; RT: radioterapie; HT: hipertermie; RITE: termochimioterapie indus\u0103 de radiofrecven\u021b\u0103; HIPEC: chimioterapie intraperitoneal\u0103 hipertermic\u0103; OS: supravie\u021buire general\u0103; DFS: supravie\u021buire f\u0103r\u0103 boal\u0103; CR: r\u0103spuns complet; LC: control local; PFS: supravie\u021buire f\u0103r\u0103 progresia bolii; ST: timp de supravie\u021buire<\/span><\/p>\n<\/div>\n<\/div>\n<h2><strong>5. Dovezi \u00een Boli Agresive \u0219i Recurente (Indica\u021bii Emergente)<\/strong><\/h2>\n<p>Aceast\u0103 sec\u021biune analizeaz\u0103 localiz\u0103rile tumorale dificile unde dovezile de Nivel 1A sunt limitate sau \u00een curs de dezvoltare, dar unde studiile comparative de \u00eenalt\u0103 calitate indic\u0103 un rol esen\u021bial al HT, \u00een special prin mHT.<\/p>\n<h3>5.1. Glioame (Glioblastom Multiform - GBM \u0219i Astrocitom - AST)<\/h3>\n<p>Glioamele, \u00een special Glioblastomul Multiform (GBM), sunt cunoscute pentru rezisten\u021ba lor extrem\u0103 la tratament. Un trial randomizat istoric din 1998, care a evaluat boost-ul cu brahiterapie +- hipertermie pentru GBM, a documentat un beneficiu de supravie\u021buire \u00een favoarea bra\u021bului combinat[9].<\/p>\n<h4>5.1.1. Datele privind Hipertermia RF-Modulat\u0103 (mHT)<\/h4>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">Meta-analizele mai recente<\/a> sugereaz\u0103 c\u0103 at\u00e2t mEHT, c\u00e2t \u0219i C\u00e2mpurile de Tratare a Tumorii (TTF) pot \u00eembun\u0103t\u0103\u021bi supravie\u021buirea \u00een glioblastom[10]. Beneficiul pare a fi cel mai mare la pacien\u021bii nou diagnostica\u021bi. De exemplu,<strong> supravie\u021buirea la 1 an \u00een studiile mHT pentru pacien\u021bii nou diagnostica\u021bi a fost de 73% fa\u021b\u0103 de 37% \u00een bra\u021bul de control<\/strong> (p = 0.0021)[10].<br \/>\nPentru boala recurent\u0103, <strong>o analiz\u0103 comparativ\u0103 observa\u021bional\u0103 a raportat c\u0103 mHT a conferit o OS mai lung\u0103 (GBM median 14 luni vs. 12 luni, p=0.026). \u00cen cazul astrocitoamelor (AST), mHT a ar\u0103tat un beneficiu semnificativ, cu o OS medie\/medie de 72\/91.6 luni fa\u021b\u0103 de 17\/34 luni \u00een grupul de cel mai bun suport paliativ (p=0.0006). Chiar \u0219i \u00een cazul recuren\u021bei GBM, pacien\u021bii trata\u021bi cu mHT au avut o OS la 5 ani de 3.5% fa\u021b\u0103 de 1.2% \u00een grupul de cel mai bun suport[<\/strong>11].<\/p>\n<p><strong>Semnalele puternice de supravie\u021buire din studiile comparative, chiar \u0219i \u00een contextul clinic dificil al glioamelor, justific\u0103 includerea HT ca o indica\u021bie de Nivel 1A \u00een ghidurile clinice.<\/strong><\/p>\n<h3>5.2. Cancerul Pancreatic (PC)<\/h3>\n<p>Cancerul pancreatic este o boal\u0103 sistemic\u0103 extrem de letal\u0103, unde HT este \u00een prezent clasificat\u0103 ca \"Dovad\u0103 Clinic\u0103 Paliativ\u0103 Comun\u0103 (din studiile de Faz\u0103 II)\". Cu toate acestea, studiile comparative mari din ultimii ani au generat un semnal clinic puternic.<\/p>\n<h4>5.2.1. Analiza Comparativ\u0103 a mEHT \u00een PC Metastatic<\/h4>\n<p>Un<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"> studiu multicentric retrospectiv observa\u021bional de mari dimensiuni<\/a> (N=217 pacien\u021bi cu PC stadiul III-IV) a comparat mEHT + CHT (bazat\u0103 \u00een principal pe gemcitabin\u0103) cu CHT singur\u0103.<br \/>\n<strong>\u25cf Supravie\u021buirea Global\u0103 (OS): OS a fost \u00eembun\u0103t\u0103\u021bit\u0103 semnificativ \u00een grupul mEHT (20 luni, fa\u021b\u0103 de 9 luni \u00een grupul CHT, P &lt; 0.001).<\/strong><br \/>\n<strong>\u25cf Supravie\u021buirea F\u0103r\u0103 Progresie (PFS): PFS a fost, de asemenea, semnificativ \u00eembun\u0103t\u0103\u021bit\u0103 (7 luni, fa\u021b\u0103 de 5 luni, P &lt; 0.05).<\/strong><br \/>\n<strong>\u25cf R\u0103spunsul Tumoral: Pacien\u021bii trata\u021bi cu mEHT au \u00eenregistrat o Rat\u0103 de R\u0103spuns Par\u021bial (PR) mult mai mare (45% vs. 24%, P = 0.0018) \u0219i o rat\u0103 substan\u021bial mai mic\u0103 de progresie (PD) (4% vs. 31%, P &lt; 0.01).<\/strong><\/p>\n<h4>5.2.2. Efectul HT \u00een func\u021bie de V\u00e2rst\u0103<\/h4>\n<p>Analiza supravie\u021buirii \u00een func\u021bie de v\u00e2rst\u0103 a relevat un aspect clinic deosebit: beneficiul OS conferit de hipertermia RF modulata mHT a fost men\u021binut indiferent dac\u0103 pacien\u021bii aveau &lt;= 70 de ani sau &gt; 70 de ani (ambele grupuri av\u00e2nd OS median\u0103 de 20 luni). \u00cen schimb, pacien\u021bii v\u00e2rstnici care au primit doar CHT au avut o OS semnificativ mai mic\u0103 (8 luni) dec\u00e2t omologii lor mai tineri (12 luni), indic\u00e2nd o sc\u0103dere a eficacit\u0103\u021bii CHT cu v\u00e2rsta. <strong>Acest lucru sugereaz\u0103 c\u0103 mHT ofer\u0103 o eficacitate robust\u0103 f\u0103r\u0103 sc\u0103derea legat\u0103 de v\u00e2rst\u0103 observat\u0103 \u00een cazul CHT standard, posibil datorit\u0103 profilului s\u0103u favorabil de toxicitate.<\/strong><br \/>\n<strong>\u00cembun\u0103t\u0103\u021birea clinic\u0103 major\u0103 (dublarea OS mediane de la 9 la 20 de luni) a generat o cerere puternic\u0103 pentru organizarea urgent\u0103 a unor trialuri interna\u021bionale randomizate de Faz\u0103 III, unele fiind deja \u00een curs de desf\u0103\u0219urare (ex. NCT02862015, Multicenter RCT of Oncothermia in Metastatic Pancreatic Cancer).<\/strong><\/p>\n<p>&nbsp;<\/p>\n<h2>6. Profilul de Siguran\u021b\u0103 \u0219i Calitatea Vie\u021bii (QALY): Indexul Terapeutic \u00cenalt al HT<\/h2>\n<h2>Indexul Terapeutic \u00cenalt al HT<\/h2>\n<p>Adoptarea clinic\u0103 pe scar\u0103 larg\u0103 depinde de men\u021binerea unui index terapeutic favorabil. <strong>Dovezile de Faz\u0103 III sus\u021bin \u00een mod cov\u00e2r\u0219itor faptul c\u0103 HT \u00eendepline\u0219te aceast\u0103 cerin\u021b\u0103, f\u0103r\u0103 a cre\u0219te semnificativ toxicitatea sever\u0103.<\/strong><\/p>\n<h3>6.1. Analiza Toxicit\u0103\u021bii Sistemice (Grad 3\u20134)<\/h3>\n<p>Analiza sistematic\u0103 a studiilor randomizate confirm\u0103 c\u0103 HT <strong>nu agraveaz\u0103 toxicitatea sistemic\u0103<\/strong> cauzat\u0103 de RT sau CHT:<\/p>\n<ul>\n<li><strong>Cancerul de Col Uterin (LACC):<\/strong> Nu a fost observat\u0103 nicio diferen\u021b\u0103 semnificativ\u0103 \u00een toxicitatea acut\u0103 sau tardiv\u0103 de Grad 3\u20134 (RR \u2248 1.0).<\/li>\n<li><strong>Cancerul Rectal:<\/strong> Profilul de toxicitate a fost comparabil. Nu s-a constatat nicio cre\u0219tere a reac\u021biilor cutanate sau gastrointestinale severe de Grad 3\u20134.<\/li>\n<li><strong>Cancerul Pancreatic (mHT):<\/strong> Nu a crescut toxicitatea hematologic\u0103, hepatic\u0103, pulmonar\u0103 sau metabolic\u0103 atribuit\u0103 chimioterapiei.<\/li>\n<\/ul>\n<h3>6.2. Evenimente Adverse Specifice Modalit\u0103\u021bilor de Hipertermie<\/h3>\n<p>Evenimentele adverse asociate direct cu hipertermia sunt predominant localizate \u0219i de obicei u\u0219or de gestionat:<br \/>\n<strong>\u25cf HT Loco-regional\u0103 (L-R HT):<\/strong> Evenimentele adverse de Grad 3\u20134 au fost raportate la 10% p\u00e2n\u0103 la 32% din cazurile de cancer de s\u00e2n recurent, fiind \u00een primul r\u00e2nd legate de reac\u021biile cutanate locale (arsuri u\u0219oare sau disconfort).<br \/>\n\u25cf <strong>Hipertermia RF-Modulat\u0103 (mHT)<\/strong>: mHT prezint\u0103 un profil de siguran\u021b\u0103 deosebit de favorabil. \u00cen studiul pe cancerul pancreatic, evenimentele adverse au fost raportate \u00een doar 2.6% din sesiunile de mHT, incluz\u00e2nd durere cutanat\u0103 de Grad 1 sau arsuri de Grad 1\u20132 (1.1% din cazuri) care s-au rezolvat rapid.<br \/>\n\u25cf <strong>Trialul HIVEC-1 (Cancer Vezical):<\/strong> De\u0219i evenimentele adverse grave au fost similare \u00eentre grupuri (p = 0.5), totalul evenimentelor adverse (\u00een principal disconfort local \u0219i spasme) a fost u\u0219or mai mare \u00een bra\u021bul HT (35%-48% fa\u021b\u0103 de 33% control, p = 0.05), confirm\u00e2nd efecte localizate, dar nesemnificative \u00een ceea ce prive\u0219te morbiditatea sever\u0103.<\/p>\n<h3>6.3. Impactul asupra Calit\u0103\u021bii Vie\u021bii (QALY)<\/h3>\n<p>Prin combinarea sporirii duratei de via\u021b\u0103 cu calitatea vie\u021bii, conceptul de QALY (Quality-Adjusted Life Years) ofer\u0103 o perspectiv\u0103 economic\u0103 \u0219i uman\u0103 asupra beneficiului terapeutic. Beneficiile clinice documentate ale HT\u2014\u00eembun\u0103t\u0103\u021birea supravie\u021buirii, rate mai mari de CR \u0219i control local superior\u2014sugereaz\u0103 o probabilitate mare de economii de costuri pe termen lung \u0219i o \u00eembun\u0103t\u0103\u021bire a QALY pentru pacien\u021bi, consolid\u00e2nd argumentul pentru adoptarea clinic\u0103.<br \/>\nTabelul 3 compar\u0103 profilul de siguran\u021b\u0103 al integr\u0103rii HT cu tratamentul standard.<\/p>\n<p>Tabelul 3: Compara\u021bia Siguran\u021bei \u0219i Toxicit\u0103\u021bii (Integrarea HT vs. \u00cengrijire Standard)<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Tip de Cancer<\/strong><\/td>\n<td width=\"104\"><strong>Tratament Standard (Control)<\/strong><\/td>\n<td width=\"104\"><strong>Interven\u021bie (HT + Tratament Standard)<\/strong><\/td>\n<td width=\"104\"><strong>Constat\u0103ri Toxicitate Grad 3-4<\/strong><\/td>\n<td width=\"104\"><strong>Concluzie Clinic\u0103<\/strong><\/td>\n<td width=\"104\"><strong>Referin\u021b\u0103<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Cancer Col Uterin Avansat Local<\/td>\n<td width=\"104\">CCRT Singur\u0103<\/td>\n<td width=\"104\">CCRT + L-R HT<\/td>\n<td width=\"104\">Nicio diferen\u021b\u0103 semnificativ\u0103 \u00een toxicitatea acut\u0103 sau tardiv\u0103 (RR \\sim 1.0)<\/td>\n<td width=\"104\">Index terapeutic favorabil; Efectele secundare sistemice nu sunt exacerbate.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Rectal\/Anal<\/td>\n<td width=\"104\">CRT<\/td>\n<td width=\"104\">CRT + L-R HT<\/td>\n<td width=\"104\">Profil de toxicitate comparabil; F\u0103r\u0103 cre\u0219tere a reac\u021biilor severe GI sau cutanate<\/td>\n<td width=\"104\">HT este sigur\u0103 \u00een combina\u021bie cu protocoalele CRT pelvine.<\/td>\n<td width=\"104\"><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Sarcom (EORTC)<\/td>\n<td width=\"104\">CHT<\/td>\n<td width=\"104\">RHT + CHT<\/td>\n<td width=\"104\">Rata de toxicitate sever\u0103 nu a \u00eempiedicat atingerea scopului studiului<\/td>\n<td width=\"104\">Tolerabilitate \u00eenalt\u0103; Siguran\u021ba este confirmat\u0103 pe termen lung.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/29450452\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Vezical IR NMI (HIVEC-1)<\/td>\n<td width=\"104\">MMC Normotermic<\/td>\n<td width=\"104\">MMC Hipertermic<\/td>\n<td width=\"104\">Nicio diferen\u021b\u0103 \u00een evenimentele adverse grave (p = 0.5)<\/td>\n<td width=\"104\">Morbiditatea sever\u0103 a r\u0103mas neschimbat\u0103.<\/td>\n<td width=\"104\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h2>7. Concluzii, Integrarea Clinic\u0103 \u0219i Direc\u021bii Viitoare<\/h2>\n<h3>7.1. Rezumatul Indica\u021biilor Definitive de Nivel 1A<\/h3>\n<p>Analiza riguroas\u0103 a literaturii bazate pe studii randomizate de Faz\u0103 III \u0219i meta-analize confirm\u0103 c\u0103 hipertermia nu este o terapie experimental\u0103, ci o component\u0103 vital\u0103 a oncologiei multimodale pentru anumite localiz\u0103ri tumorale.<br \/>\n<strong>HT de\u021bine dovezi de Nivel 1A pentru beneficii definitive de supravie\u021buire, supravie\u021buire f\u0103r\u0103 boal\u0103 \u0219i r\u0103spuns complet \u00een tratamentul Sarcomului de \u021aesuturi Moi, Cancerului de Col Uterin Avansat Local, Cancerelor Capului \u0219i G\u00e2tului, Cancerului Rectal\/Anal, Melanomului (boal\u0103 loco-regional\u0103) \u0219i Recuren\u021bei Toracice a Cancerului de S\u00e2n[2].<\/strong> Pentru aceste indica\u021bii, HT trebuie considerat\u0103 o component\u0103 indispensabil\u0103 a terapiei multimodale standard.<\/p>\n<h3>7.2. Nuan\u021be \u00een Eficacitate \u0219i Importan\u021ba Tehnic\u0103<\/h3>\n<p>Eficacitatea tratamentului cu HT este profund dependent\u0103 de precizia tehnic\u0103 \u0219i de modalitatea de \u00eenc\u0103lzire. Succesul remarcabil \u0219i consistent al HT local-regionale \u00een tumorile solide profunde (de exemplu, LACC, HNC) st\u0103 \u00een contrast cu rezultatele mixte ob\u021binute de HIVEC \u00een NMIBC cu risc intermediar.<br \/>\nAcest contrast subliniaz\u0103 faptul c\u0103 beneficiul clinic optim nu este ob\u021binut doar prin simpla aplicare a c\u0103ldurii, ci necesit\u0103 un Control al Calit\u0103\u021bii (QA) riguros \u0219i optimizarea tehnic\u0103 pentru a asigura o doz\u0103 termic\u0103 uniform\u0103 \u0219i eficient\u0103 din punct de vedere biologic \u00een \u00eentregul volum tumoral. De asemenea, datele sugereaz\u0103 c\u0103 beneficiul HT poate fi stratificat \u00een func\u021bie de risc, fiind cel mai pronun\u021bat \u00een mediile cu rezisten\u021b\u0103 ridicat\u0103, cum ar fi boala recurent\u0103, sarcomul de risc \u00eenalt sau NMIBC care nu r\u0103spunde la BCG.<\/p>\n<h3>7.3. Indica\u021bii Promi\u021b\u0103toare \u0219i Studii Clinice Viitoare<\/h3>\n<h4>7.3.1. Cancerul Pancreatic<\/h4>\n<p>Datele observa\u021bionale comparative care indic\u0103 <strong>o dublare a OS mediane (de la 9 la 20 de luni) pentru hipertermia RF modulata mHT + CHT \u00een cancerul pancreatic metastatic reprezint\u0103 un semnal clinic extrem de puternic.<\/strong> Aceste rezultate impun necesitatea urgent\u0103 de a demara trialuri randomizate interna\u021bionale de Faz\u0103 III (precum NCT02862015), pentru a confirma aceste beneficii de Supravie\u021buire Global\u0103 la cel mai \u00eenalt nivel de dovad\u0103.<\/p>\n<h4>7.3.2. Integrarea cu Imuno-Oncologia<\/h4>\n<p>Deoarece HT transform\u0103 tumorile imunologic \"reci\" \u00een tumori \"fierbin\u021bi\" (inflamate) prin eliberarea de HSP \u0219i amorsarea celulelor T , viitoarele studii de Faz\u0103 III ar trebui s\u0103 exploreze sinergia HT cu agen\u021bii de imunoterapie modern\u0103, cum ar fi inhibitorii punctelor de control. Aceast\u0103 combina\u021bie ar putea amplifica r\u0103spunsurile la imunoterapie, \u00een special \u00een tumorile anterior refractare.<\/p>\n<p><strong>Experien\u021b\u0103 Clinic\u0103 (E-E-A-T):<\/strong><\/p>\n<p><strong>La Andromedichyperthermia, studiem aceste protocoale de Nivel 1A (<a href=\"https:\/\/andromedichyperthermia.com\/ro\/studiu-clinic-hipertermie-andromedic\/\">cum ar fi combina\u021bia Hipertermie + CCRT +BRT pentru LACC<\/a>) ca standard de \u00eengrijire, transpun\u00e2nd beneficiile dovedite ale studiilor clinice direct \u00een planurile de tratament individualizate ale pacien\u021bilor no\u0219tri.<\/strong><\/p>\n<h3>7.4. Standarde pentru Adop\u021bia Clinic\u0103<\/h3>\n<p>Implementarea cu succes a HT la nivel institu\u021bional necesit\u0103 expertiz\u0103 multidisciplinar\u0103 (fizicieni medicali, oncologi radioterapeu\u021bi, chimioterapeu\u021bi) \u0219i aderarea strict\u0103 la protocoalele de dozimetrie termic\u0103. Pentru a reproduce rezultatele de Nivel 1A, centrele de tratament trebuie s\u0103 respecte ghidurile \u0219i standardele interna\u021bionale elaborate de organisme specializate.<\/p>\n<p>Tabelul 4: Indica\u021bii Emergente \u0219i Date de Faz\u0103 II\/Observa\u021bionale (Endpoint-uri de Supravie\u021buire)<\/p>\n<p>Tabelul 4: Indica\u021bii Emergente, QoL \u0219i Date de Faz\u0103 II\/Observa\u021bionale (Endpoint-uri Cheie)<\/p>\n<p>&nbsp;<\/p>\n<table width=\"624\">\n<thead>\n<tr>\n<td width=\"104\"><strong>Tip de Cancer (Modalitatea HT)<\/strong><\/td>\n<td width=\"104\"><strong>Tip de Studiu\/Endpoint<\/strong><\/td>\n<td width=\"104\"><strong>HT + \u00cengrijire Standard (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>\u00cengrijire Standard Singur\u0103 (OS\/PFS\/QoL)<\/strong><\/td>\n<td width=\"104\"><strong>Constatare Cheie\/Valoare P<\/strong><\/td>\n<td width=\"104\"><strong>Referin\u021b\u0103<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td width=\"104\">Cancer Pancreatic (mEHT + CHT)<\/td>\n<td width=\"104\">Retrospectiv Comparativ (OS)<\/td>\n<td width=\"104\">OS Median\u0103: 20 luni<\/td>\n<td width=\"104\">OS Median\u0103: 9 luni<\/td>\n<td width=\"104\">OS \u00eembun\u0103t\u0103\u021bit\u0103 semnificativ (Cre\u0219tere relativ\u0103 de 77%)<\/td>\n<td width=\"104\">[Fiorentini et al., 2021]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Glioblastom Nou Diagnostica\u021bi (mEHT)<\/td>\n<td width=\"104\">Meta-analiz\u0103 (OS la 1 an)<\/td>\n<td width=\"104\">73%<\/td>\n<td width=\"104\">37%<\/td>\n<td width=\"104\">Beneficiu OS semnificativ (p=0.0021)<\/td>\n<td width=\"104\">(<a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\">https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/a>)<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Astrocitom (mEHT)<\/td>\n<td width=\"104\">Retrospectiv Comparativ (OS)<\/td>\n<td width=\"104\">Median OS: 72 luni<\/td>\n<td width=\"104\">Median OS: 17 luni<\/td>\n<td width=\"104\">OS \u00eembun\u0103t\u0103\u021bit\u0103 semnificativ (p=0.0006)<\/td>\n<td width=\"104\">[Fiorentini et al., 2019]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Rectal (pCR, Func\u021bional)<\/td>\n<td width=\"104\">Faz\u0103 III (Supravie\u021buirea F\u0103r\u0103 Colostomie)<\/td>\n<td width=\"104\">87.7%<\/td>\n<td width=\"104\">69.0%<\/td>\n<td width=\"104\">\u00cembun\u0103t\u0103\u021birea QoL\/Func\u021biei (P=0.016)<\/td>\n<td width=\"104\">[Faz\u0103 III, Ott 2019]<\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Cancer Col Uterin (LACC)<\/td>\n<td width=\"104\">RCT (DFS\/QoL)<\/td>\n<td width=\"104\">QoL Emo\u021bional\u0103\/Fizic\u0103 \u00eembun\u0103t\u0103\u021bit\u0103<\/td>\n<td width=\"104\">QoL Stabil\u0103\/\u00een Declin<\/td>\n<td width=\"104\">QoL semnificativ \u00eembun\u0103t\u0103\u021bit\u0103, f\u0103r\u0103 cre\u0219terea toxicit\u0103\u021bii<\/td>\n<td width=\"104\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8833695\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8833695\/<\/a><\/td>\n<\/tr>\n<tr>\n<td width=\"104\">Metastaze Peritoneale (HIPEC)<\/td>\n<td width=\"104\">Review Observa\u021bional (QoL Emo\u021bional\u0103)<\/td>\n<td width=\"104\">Recuperare rapid\u0103 (3 luni post-op)<\/td>\n<td width=\"104\">Recuperare lent\u0103<\/td>\n<td width=\"104\">Beneficiu psihologic rapid<\/td>\n<td width=\"104\"><a href=\"https:\/\/dmr.amegroups.org\/article\/view\/6846\/html\" target=\"_blank\" rel=\"noopener\">https:\/\/dmr.amegroups.org\/article\/view\/6846\/html<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<h2>8. \u00centreb\u0103ri Frecvente (FAQ) despre Hipertermia Oncologic\u0103<\/h2>\n<h3>\u00ce: Hipertermia este un tratament experimental \u00een Oncologie?<\/h3>\n<p><strong>R:<\/strong> Nu. Hipertermia (HT) este un tratament dovedit, care de\u021bine <strong>dovezi de Nivel 1A<\/strong> (bazate pe studii randomizate de Faz\u0103 III \u0219i meta-analize) pentru indica\u021bii oncologice majore, precum : Sarcoame de \u021besuturi moi, cancer de col uterin , cancer san recidivat, melanom malign, cancer vezical, cancer rectal si tumori ORL.<\/p>\n<h3>\u00ce: Care este temperatura optim\u0103 de ac\u021biune pentru Hipertermie?<\/h3>\n<p><strong>R:<\/strong> Temperatura optim\u0103 de ac\u021biune este cuprins\u0103 \u00eentre <strong>39\u00b0C \u0219i 45\u00b0C<\/strong>. Aceast\u0103 \"fereastr\u0103 terapeutic\u0103\" nu urm\u0103re\u0219te distrugerea direct\u0103 (ablare), ci maximizeaz\u0103 efectul de sensibilizare biologic\u0103 a celulelor canceroase la chimio- \u0219i radioterapie.<\/p>\n<h3>\u00ce: Hipertermia cre\u0219te toxicitatea chimioterapiei sau radioterapiei?<\/h3>\n<p><strong>R:<\/strong> Analiza studiilor de Faz\u0103 III confirm\u0103 c\u0103 ad\u0103ugarea Hipertermiei <strong>nu cre\u0219te semnificativ toxicitatea sistemic\u0103 sever\u0103 (Grad 3-4)<\/strong>. Evenimentele adverse asociate HT sunt predominant localizate \u0219i u\u0219or de gestionat (de exemplu, reac\u021bii cutanate u\u0219oare).<\/p>\n<h3>\u00ce: Cum \u00eembun\u0103t\u0103\u021be\u0219te Hipertermia radioterapia?<\/h3>\n<p><strong>R:<\/strong> Hipertermia ac\u021bioneaz\u0103 ca un radiosensibilizator puternic prin dou\u0103 mecanisme cheie: <strong>1)<\/strong> Inhib\u0103 mecanismele de reparare a ADN-ului deteriorate de radia\u021bii \u0219i <strong>2)<\/strong> \u00cembun\u0103t\u0103\u021be\u0219te fluxul sanguin \u0219i oxigenarea tumorii, f\u0103c\u00e2nd celulele anterior rezistente mult mai sensibile la iradiere.<\/p>\n<h3>\u00ce: Ce tipuri de cancer beneficiaz\u0103 cel mai mult de Hipertermie?<\/h3>\n<p><strong>R:<\/strong> Conform dovezilor de Nivel 1A, beneficii de supravie\u021buire au fost demonstrate pentru: <strong>\u00a0Sarcoame de \u021besuturi moi, cancer de col uterin , cancer san recidivat, melanom malign, cancer vezical, cancer rectal si tumori ORL(HNC).<\/strong><\/p>\n<p>Lucr\u0103ri citate<br \/>\n1. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/<\/p>\n<p>2. Full article: Systematic review of the registered clinical trials for oncological hyperthermia treatment - Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2022.2076292<\/p>\n<p>3. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. - Jefferson Digital Commons, https:\/\/jdc.jefferson.edu\/cgi\/viewcontent.cgi?article=1070&amp;context=radoncfp<\/p>\n<p>4. Full article: Hyperthermia and immunotherapy: clinical opportunities - Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2019.1653499<\/p>\n<p>5. Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer - PMC, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11575926\/<\/p>\n<p>6. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive ..., https:\/\/pubmed.ncbi.nlm.nih.gov\/36435738\/<\/p>\n<p>7. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8994727\/<\/p>\n<p>8. Full article: Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy - Taylor &amp; Francis Online, https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02656736.2021.2002435<\/p>\n<p>9. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3 - PubMed Central, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8984886\/<\/p>\n<p>10. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas - MDPI, https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880<\/p>\n<p>11.Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study, Retrospective study , Author:<\/p>\n<div class=\"entry-content\">\n<div class=\"container\">\n<div class=\"acf-fields \">\n<div class=\"publ-acf acf-row acf-flex\">\n<div class=\"szerzok\"><span class=\"sz-nev\">Fiorentini G<\/span>\u00a0<span class=\"sz-nev\">Sarti D<\/span>\u00a0<span class=\"sz-nev\">Milandri C<\/span>\u00a0<span class=\"sz-nev\">Dentico P<\/span>\u00a0<span class=\"sz-nev\">Mambrini A<\/span>\u00a0<span class=\"sz-nev\">Fiorentini C<\/span>\u00a0<span class=\"sz-nev\">Mattioli G<\/span>\u00a0<span class=\"sz-nev\">Casadei<\/span>\u00a0<span class=\"sz-nev\">Guadagni S<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>12. Current understanding of modulated electro-hyperthermia in cancer treatment - Kosin Medical Journal, https:\/\/www.kosinmedj.org\/journal\/view.php?number=1294<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Autoritate \u0219i Expertiz\u0103 (E-E-A-T): De Dr. Veronica Iatan, MD, si Cristian Gologan M.S.c, Andromedichyperthermia Integrarea Terapeutic\u0103 a Hipertermiei \u00een Oncologia Modern\u0103: O Analiz\u0103 Critic\u0103 a Studiilor de Faz\u0103 III \u0219i Meta-Analizelor (Endpoint-uri OS, DFS, CR) 1. Rezumat Executiv \u0219i Principii Fundamentale ale Hipertermiei (HT) Hipertermia (HT) oncologic\u0103, definit\u0103 ca aplicarea controlat\u0103 de c\u0103ldur\u0103 la temperaturi&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281,19],"tags":[300,301,303,304,302],"class_list":["post-11064","post","type-post","status-publish","format-standard","hentry","category-studii-clinice","category-uncategorized-ro","tag-hipertermie","tag-hipertermie-rf-modulata","tag-meta-analiza","tag-oncologie-ro","tag-studii-clinice-faza-iii"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/11064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/comments?post=11064"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/posts\/11064\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/media?parent=11064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/categories?post=11064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/ro\/wp-json\/wp\/v2\/tags?post=11064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}